COVID-19: Vaccine Information, Visitor Information and What to Expect

Montlake Bridge Closure: Learn about detours to Seattle Children’s when the Montlake Bridge closes during several weekends this fall.

Learn about Seattle Children’s Health Equity and Anti-Racism Action Plan, a message from Dr. Jeff Sperring, CEO.

Current Research Studies

Cancer – SC-4017: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Condition or Therapy:

cancer, medullary thyroid cancer, infantile myofibromatosis, infantile fibrosarcoma, papillary thyroid cancer, soft tissue sarcoma, LOXO-292 therapy

Category:

Cancer and Blood Disorders
Study Number: SC-4017

What is the goal of this study?

Researchers want to determine safety of LOXO-292 and overall response rate to LOXO-292

Who can join the study?

This study may be a good fit for children and young adults who:

Are between 6 months to 21 years old, and
Have advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies
Have evidence of an activating RET gene alteration in the tumor and/ or blood

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Katie Albert
Research Center: Center for Clinical and Translational Research

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2021 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.